OCON Healthcare’s first-ever 3D spherical copper intrauterine contraceptive.
OCON Healthcare, an Israeli FemTech startup, manufactures and commercializes innovative 3D intrauterine devices (IUD) based on its patented IUB (Intra-Uterine Ball) platform. The company has appointed a woman to lead it, Dr. Anula Jayasuriya. It has also just completed a major round of funding in the U.S.
Contraception is central to women’s issues. An IUD is a device that gets implanted into a woman’s body. And it can be removed if the user wishes to conceive. This gives women a higher level of freedom and control over their own bodies.
Progress in FemTech is synonymous with Progress for women in the world in general. In this way, Startup Nation not only takes a lead in high tech, but also in the advancement of women’s rights.
–
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Founded in 2011 and based in Modiin, Israel, OCON Healthcare declares that its mission is to provide innovative, high-quality intrauterine drug-delivery technology to” improve women’s health and quality of life.”
Its product, the IUB Ballerine, is a birth control method that requires no hormones and which the company states is effective for up to 5 years. The IUB Ballerine works along the same principle as other intrauterine devices and prevents pregnancy locally – within the uterus.
Once in the uterus, the device releases small amounts of copper to provide continuous birth control. The method of action is similar to standard copper intrauterine devices.
Due to the special form and material, OCON says that the IUB Ballerine ideally conforms to the shape of the uterus and minimizes risk of damage and irritation. The device is commercially available in 30 countries with over 100,000 women using it to date.
